Targeting the mitogen-activated protein kinase cascade to treat cancer
Top Cited Papers
- 1 December 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 4 (12) , 937-947
- https://doi.org/10.1038/nrc1503
Abstract
The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?Keywords
This publication has 81 references indexed in Scilit:
- A Hot Spot for Protein Kinase Inhibitor SensitivityChemistry & Biology, 2004
- Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in VitroPublished by Elsevier ,2003
- Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytesBiochemical Journal, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- The RAS Effector RIN1 Directly Competes with RAF and Is Regulated by 14-3-3 ProteinsMolecular and Cellular Biology, 2002
- Anchorage-dependent ERK signaling – mechanisms and consequencesCurrent Opinion in Genetics & Development, 2002
- Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer CellsPublished by Elsevier ,2001
- Ordered phosphorylation of p42mapk by MAP kinase kinaseFEBS Letters, 1992